Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and cancer. The company’s portfolio encompasses sequencing kits and reagents; sequencing tools and systems; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; instrument services, training, and consulting. The company serves pharmaceutical companies, academic institutions, genomic research centers, biotechnology companies and clinical research organizations. The company sells its products through direct sales and distributors in the Americas, Asia-Pacific, Europe, the Middle East, and Africa. Illumina is headquartered in San Diego, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Illumina Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Illumina Inc Company Overview
Illumina Inc Company Snapshot
Illumina Inc Pipeline Products and Ongoing Clinical Trials Overview
Illumina Inc – Pipeline Analysis Overview
Business Description
Illumina Inc - Key Facts
Illumina Inc - Major Products and Services
Illumina Inc Pipeline Products by Development Stage
Illumina Inc Ongoing Clinical Trials by Trial Status
Illumina Inc Pipeline Products Overview
Blood-Based Test - Breast Cancer
Blood-Based Test - Breast Cancer Product Overview
Blood-Based Test - Breast Cancer Clinical Trial
Blood-Based Test - Lung Cancer
Blood-Based Test - Lung Cancer Product Overview
Blood-Based Test - Lung Cancer Clinical Trial
Companion Diagnostic Test - Brain Cancer
Companion Diagnostic Test - Brain Cancer Product Overview
Companion Diagnostic Test - Cancer
Companion Diagnostic Test - Cancer Product Overview
Companion Diagnostic Test - Colorectal Cancer
Companion Diagnostic Test - Colorectal Cancer Product Overview
Companion Diagnostic Test - Head And Neck Squamous Cell Carcinoma
Companion Diagnostic Test - Head And Neck Squamous Cell Carcinoma Product Overview
Companion Diagnostic Test - Lung Cancer
Companion Diagnostic Test - Lung Cancer Product Overview
Companion Diagnostic Test - Melanoma
Companion Diagnostic Test - Melanoma Product Overview
Companion Diagnostic Test - Oncology
Companion Diagnostic Test - Oncology Product Overview
Companion Diagnostic Test - Prostate Cancer
Companion Diagnostic Test - Prostate Cancer Product Overview
Companion Diagnostic Test - Pseudomonas Aeruginosa Infection
Companion Diagnostic Test - Pseudomonas Aeruginosa Infection Product Overview
Diagnostic Aid For Cancer (DAC) Test
Diagnostic Aid For Cancer (DAC) Test Product Overview
Diagnostic Test - Infectious Diseases
Diagnostic Test - Infectious Diseases Product Overview
Explify Test - CNS Infections
Explify Test - CNS Infections Product Overview
Galleri Test
Galleri Test Product Overview
Galleri Test Clinical Trial
HRD CDx Test
HRD CDx Test Product Overview
InfiniumDx CytoSNP-12 Assay
InfiniumDx CytoSNP-12 Assay Product Overview
Integrated MiniSeq System
Integrated MiniSeq System Product Overview
Lab-On-A-Chip
Lab-On-A-Chip Product Overview
Long Read Human Whole Genome Assay
Long Read Human Whole Genome Assay Product Overview
May 29, 2024: Illumina Drives Genomic Testing as Standard of Care in Oncology Through Collaborative Research Presented at ASCO
May 09, 2024: CNIO Will Help to Improve Cancer Prevention and Personalized Diagnosis with the Most Powerful ‘Gene Reader’
Mar 27, 2024: GRAIL Presents New Data on Galleri and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting
Mar 25, 2024: Nucleus Genomics launches to bring whole-genome sequencing to the public
Mar 18, 2024: Grail Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
Feb 27, 2024: Jenny Zheng Joins Illumina as Senior Vice President and General Manager of Greater China
Feb 16, 2024: Getlabs to offer GRAIL’s early cancer detection test
Feb 08, 2024: Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
Feb 01, 2024: Curative Insurance Company Adds Grail’s Galleri Test to Member Benefits for Multi-Cancer Early Detection
Jan 30, 2024: GRAIL Partners With Professional Golfers Steve Stricker and Juli Inkster to Raise Awareness of Multi-Cancer Early Detection at Second Annual Galleri Classic PGA TOUR Champions Tournament
Table 10: Blood-Based Test - Breast Cancer - Product Status
Table 11: Blood-Based Test - Breast Cancer - Product Description
Table 12: Blood-Based Test - Breast Cancer - Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection: The STRIVE Study
Table 13: Blood-Based Test - Lung Cancer - Product Status
Table 14: Blood-Based Test - Lung Cancer - Product Description
Table 15: Blood-Based Test - Lung Cancer - The SUMMIT Study: Cancer Screening Study with or Without Low Dose Lung CT to Validate a Multi-cancer Early Detection Test
Table 16: Companion Diagnostic Test - Brain Cancer - Product Status
Table 17: Companion Diagnostic Test - Brain Cancer - Product Description
Table 18: Companion Diagnostic Test - Cancer - Product Status
Table 19: Companion Diagnostic Test - Cancer - Product Description
Table 20: Companion Diagnostic Test - Colorectal Cancer - Product Status
Table 21: Companion Diagnostic Test - Colorectal Cancer - Product Description
Table 22: Companion Diagnostic Test - Head And Neck Squamous Cell Carcinoma - Product Status
Table 23: Companion Diagnostic Test - Head And Neck Squamous Cell Carcinoma - Product Description
Table 24: Companion Diagnostic Test - Lung Cancer - Product Status
Table 25: Companion Diagnostic Test - Lung Cancer - Product Description
Table 26: Companion Diagnostic Test - Melanoma - Product Status
Table 27: Companion Diagnostic Test - Melanoma - Product Description
Table 28: Companion Diagnostic Test - Oncology - Product Status
Table 29: Companion Diagnostic Test - Oncology - Product Description
Table 30: Companion Diagnostic Test - Prostate Cancer - Product Status
Table 31: Companion Diagnostic Test - Prostate Cancer - Product Description
Table 32: Companion Diagnostic Test - Pseudomonas Aeruginosa Infection - Product Status
Table 34: Diagnostic Aid For Cancer (DAC) Test - Product Status
Table 35: Diagnostic Aid For Cancer (DAC) Test - Product Description
Table 36: Diagnostic Test - Infectious Diseases - Product Status
Table 37: Diagnostic Test - Infectious Diseases - Product Description
Table 38: Explify Test - CNS Infections - Product Status
Table 39: Explify Test - CNS Infections - Product Description
Table 40: Galleri Test - Product Status
Table 41: Galleri Test - Product Description
Table 42: Galleri Test - A Randomized, Controlled Trial to Assess the Clinical Utility of a Multi-cancer Early Detection (MCED) Test for Population Screening in the United Kingdom (UK) When Added to Standard of Care
Table 43: Galleri Test - A Study to Evaluate the Galleri Blood Test in the Multi-cancer Early Detection Test
Table 44: Galleri Test - Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity
Table 45: Galleri Test - REFLECTION: Real World Evidence for Learnings in Early Cancer Detection, a Clinical Practice Learning Program for Galleri
Table 46: Galleri Test - The Circulating Cell-free Genome Atlas Study
Table 47: Galleri Test - The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-cancer Early Detection Test in an Eligible Screening Population
Table 48: Galleri Test - Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combined With GRAIL Galleri Testing to Improve Early Detection
Table 49: HRD CDx Test - Product Status
Table 50: HRD CDx Test - Product Description
Table 51: InfiniumDx CytoSNP-12 Assay - Product Status
Table 89: TruSight Oncology 500 HRD - Molecular Landscape Involved in the Onset of Breast Cancer in Patients With Germline BRCA-1/2 Mutations, During or After Therapy With Platinum-based Agents and/or PARP-inhibitors for Ovarian Cancer